Hepatitis C virus peptide compositions and methods of use thereof

US12048742B2 · kind B2 · utility

Assignee

• The Governors of the University of Alberta · CA

Inventors

• Michael Houghton · Berkeley, US
• Abdolamir Landi · Edmonton, CA
• Michael Logan · Edmonton, CA
• John L. Law · Edmonton, CA
• Chao Chen · Edmonton, CA
• Darren Hockman · Edmonton, CA

Key dates

• Filing date: Mar 14, 2019
• Grant date: Jul 30, 2024
• Expiry date: Apr 26, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2770/24234
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; ii) an HCV E1 polypeptide; or iii) an HCV E2 polypeptide; b) a polypeptide (also referred to herein as a “T-cell epitope polypeptide” or an “HCV T-cell epitope polypeptide”) comprising T-cell epitopes (e.g., CD4+ and CD8+ T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or multiple HLA alleles common within the human population) present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide.